Central Pacific Bank Trust Division Buys New Stake in Haleon plc (NYSE:HLN)

Central Pacific Bank Trust Division bought a new stake in Haleon plc (NYSE:HLNFree Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 56,776 shares of the company’s stock, valued at approximately $474,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Wellington Management Group LLP increased its stake in Haleon by 164.6% in the fourth quarter. Wellington Management Group LLP now owns 13,542,346 shares of the company’s stock valued at $111,454,000 after acquiring an additional 8,423,475 shares during the period. Patrick M Sweeney & Associates Inc. acquired a new position in Haleon in the fourth quarter valued at about $1,083,000. Douglas Lane & Associates LLC boosted its position in Haleon by 2.1% in the first quarter. Douglas Lane & Associates LLC now owns 8,401,876 shares of the company’s stock valued at $71,332,000 after buying an additional 175,082 shares in the last quarter. Capstone Investment Advisors LLC acquired a new position in Haleon in the first quarter valued at about $1,969,000. Finally, Procyon Advisors LLC boosted its position in Haleon by 559.9% in the first quarter. Procyon Advisors LLC now owns 131,665 shares of the company’s stock valued at $1,118,000 after buying an additional 111,713 shares in the last quarter. Institutional investors own 6.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on HLN. Berenberg Bank began coverage on shares of Haleon in a research report on Wednesday, June 5th. They issued a “buy” rating on the stock. Argus restated a “buy” rating on shares of Haleon in a research report on Tuesday, March 26th. Finally, HSBC began coverage on shares of Haleon in a research report on Wednesday, April 17th. They issued a “buy” rating on the stock. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy”.

Check Out Our Latest Analysis on HLN

Haleon Price Performance

Shares of HLN stock traded up $0.04 during trading hours on Wednesday, reaching $8.65. 388,276 shares of the company were exchanged, compared to its average volume of 5,245,492. Haleon plc has a fifty-two week low of $7.70 and a fifty-two week high of $8.96. The stock’s fifty day moving average is $8.42 and its two-hundred day moving average is $8.36. The company has a market cap of $39.50 billion, a price-to-earnings ratio of 28.72, a P/E/G ratio of 2.25 and a beta of 0.24. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.04 and a quick ratio of 0.73.

Haleon (NYSE:HLNGet Free Report) last announced its earnings results on Wednesday, May 1st. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.11 by $0.01. Haleon had a net margin of 9.68% and a return on equity of 13.17%. The company had revenue of $3.70 billion for the quarter, compared to analyst estimates of $3.71 billion. Sell-side analysts forecast that Haleon plc will post 0.46 earnings per share for the current fiscal year.

About Haleon

(Free Report)

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.

Read More

Want to see what other hedge funds are holding HLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haleon plc (NYSE:HLNFree Report).

Institutional Ownership by Quarter for Haleon (NYSE:HLN)

Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.